Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer.

MLA

Moore, Assaf, et al. “Long-Term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-Risk Prostate Cancer.” European Urology Oncology, vol. 7, no. 4, Aug. 2024, pp. 812–20. EBSCOhost, https://doi.org/10.1016/j.euo.2023.10.019.

APA

Moore, A., Kollmeier, M. A., McBride, S. M., Toumbacaris, N., Zhang, Z., Lacy-Elsayegh, A., Dreyfuss, A., Grossman, C. E., Gorovets, D., & Zelefsky, M. J. (2024). Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer. European Urology Oncology, 7(4), 812–820. https://doi.org/10.1016/j.euo.2023.10.019

Chicago

Moore, Assaf, Marisa A Kollmeier, Sean M McBride, Nicolas Toumbacaris, Zhigang Zhang, Ahmed Lacy-Elsayegh, Alexandra Dreyfuss, Craig E Grossman, Daniel Gorovets, and Michael J Zelefsky. 2024. “Long-Term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-Risk Prostate Cancer.” European Urology Oncology 7 (4): 812–20. doi:10.1016/j.euo.2023.10.019.